Pazopanib for the first-line treatment of advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA215
  • Published: 
  • Last updated: 
Download guidance (PDF)

6 Recommendations for further research

6.1

An ongoing head-to-head study of pazopanib versus sunitinib (COMPARZ) is due to report in June 2012.